Civitas Therapeutics has announced the appointment of former MAP Pharmaceuticals CEO Timothy S. Nelson as Chairman of the board of directors.
Nelson commented, “Civitas has a highly-validated drug inhalation platform, a potentially transformative Parkinson’s therapy with important upcoming clinical data and a management team with an exceptional record of execution. This unique combination provides a strong foundation to build a company with a robust portfolio of differentiated therapies. I am delighted to be joining the Civitas Board and look
forward to supporting the team as they deliver on the company’s remarkable promise.”
Civitas CEO and Co-founder Glenn Batchelder said, “Tim brings an exceptional track record of transformative leadership and company building across a broad range of therapeutic and medical device domains. His recent experience leading MAP Pharmaceuticals, initially as a privately-held platform company and ultimately as a publicly-traded late stage development company will be particularly relevant in helping to guide Civitas’ continued growth. With our shared focus on improving patients’ lives and his proven talent for building shareholder value, we are pleased to welcome Tim as Chairman of the Board.”
Civitas also announced the completion of enrollment in an ongoing Phase 2b clinical study of CVT-301 inhaled L-dopa for the treatment of motor fluctuations in Parkinson’s Disease patients. The company says that it expects to have data from the study within several months.
Read the Civitas press release.
